Skip to main content
Equibles
OPRX logo

OPRX · OptimizeRx Corp · Metrics

Track OPRX — free

Use OPRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research OPRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$7.15 -0.02 (-0.28%)
Rebalance outlook locked
Customer concentration — top 5 customers 47% of revenue

5 customers — 47% of revenue (the year ended December 31, 2025)

“Our top five customers represented approximately 47% and 49% of our revenue for the years ended December 31, 2025 and 2024, respectively.”

One customer — 10% of revenue (fiscal 2025)

“one customer that accounted for approximately 10% of total revenue in fiscal 2025 did not generate revenue during the current period, and future revenue from this customer is uncertain.”

3 customers — 10% of revenue (2025)

“In 2025 and 2024, we had three customers and two customers, respectively, that represented more than 10% of our revenues.”

5 customers — 49% of revenue (the year ended December 31, 2024)

“Our top five customers represented approximately 47% and 49% of our revenue for the years ended December 31, 2025 and 2024, respectively.”

2 customers — 10% of revenue (2024)

“In 2025 and 2024, we had three customers and two customers, respectively, that represented more than 10% of our revenues.”
View the 10-Q filed Aug 13, 2026
Market Cap
$135.05M
Shares
18.84M

OPRX metrics

81 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$7.17
Market cap
$135.05M

Price action

20 metrics
Price change (1W)
-3.3%
Price change (30D)
+10.8%
Price change (3M)
+49.9%
Price change (6M)
+15.5%
Price change (YTD)
-38.0%
Price change (1Y)
-58.4%
Trailing year
Price change (5Y)
-88.6%
52-week high
$21.68
52-week low
$4.54
Change from 52-week high
-64.9%
Change from 52-week low
+67.4%
Annualized volatility
72.9%
Annualized volatility (3M)
67.3%
Beta
2.0
RSI (14D)
51.0
Price vs SMA 50
+8.4%
Price vs SMA 200
-8.5%
Avg volume (3M)
309,021
Relative volume
0.3
Average dollar volume
$1.94M

Company

3 metrics
Sector
Healthcare
Industry
Health Information Services
Shares outstanding
18.84M

Valuation

12 metrics
P / E (TTM)
31.7
Trailing earnings · reciprocal yield 3.2%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.4×
reciprocal yield 73.0%
P / book
1.0
reciprocal yield 97.1%
FCF yield
13.6%
TTM · current market cap
Buyback yield
—
P / FCF
7.4
reciprocal yield 13.6%
P / operating cash flow
7.3
reciprocal yield 13.6%
Earnings yield
3.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
712.6×
reciprocal yield 0.1%
EV / revenue historical average (3Y)
2.1×
reciprocal yield 48.1%
EV / revenue historical average (5Y)
2.1×
reciprocal yield 48.1%
EV / EBIT historical average (3Y)
18.9×
reciprocal yield 5.3%
EV / EBIT historical average (5Y)
18.9×
reciprocal yield 5.3%
EV / EBITDA historical average (3Y)
142.1×
reciprocal yield 0.7%
EV / EBITDA historical average (5Y)
142.1×
reciprocal yield 0.7%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-12

Profitability

9 metrics
Gross margin
67.3%
Operating margin
11.0%
Trailing 12 months
Net margin
4.7%
Gross profit (TTM)
$73.59M
Operating profit (TTM)
$10.90M
Net income (TTM)
$4.60M
Trailing 12 months
Diluted EPS (TTM)
$0.24
FCF margin
18.6%
Effective tax rate
31.8%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$6.84

Growth

11 metrics
Revenue growth YoY
-29.8%
Year over year
Net income growth YoY
-145.9%
Revenue (TTM)
$98.65M
Trailing 12 months
EPS growth YoY
-150.0%
Shares change YoY
-1.2%
Year over year · fewer shares
Revenue CAGR (3Y)
+20.6%
Revenue CAGR (5Y)
+20.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
+20.8%
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
3.5%
Return on assets
2.8%
Debt / equity
0.1
Current ratio
5.6
EBITDA (TTM)
$15.18M
Free cash flow (TTM)
$18.36M
Quick ratio
5.6
Interest coverage
2.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$24.10M
Total assets
$164.32M
Total debt
$19.01M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$18.43M
Capital expenditures (TTM)
$77,000
R&D (TTM)
$332,000
SG&A (TTM)
$36.28M
Stock compensation (TTM)
$7.95M
R&D / revenue
—
Stock compensation / revenue
8.1%

Ownership (13F)

3 metrics
13F filers
112
13F filer change QoQ
-18
Institutional ownership
60.3%

Short interest

3 metrics
Short interest
6.1%
Latest settlement · 3.8 days to cover
Days to cover
3.8d
Short-squeeze score
66 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1448431 CUSIP 68401U204 13F (30d) 75 filings 75 filers Visit website Investor relations